This study examined 216 COVID-19 patients, focusing on cardiovascular complications and comparing outcomes based on demographics, cardiovascular assessments, and vascular issues. Findings showed that ICU patients and those who died were older than recovered patients. Each additional year of age increased the odds of ICU hospitalization by 1.032 times and mortality by 1.062 times. These results are consistent with other research, such as Bonanad et al.'s meta-analysis, which also found higher mortality rates in older COVID-19 patients (
13). Previous studies indicate that males had higher COVID-19 mortality rates than females, but the difference was not statistically significant (
14). The study found mortality rates of 15.7% in males and 14.2% in females. Cohen et al. reported higher hospitalization rates for ages 30 - 69, while ICU admissions for those over 70 were lower than in younger groups (
15). This difference in hospitalization rates may stem from an age-based approach to admission, especially when ICU beds were limited during COVID-19 in many areas (
16).
In the study, 14.5% of hospitalized COVID-19 patients tested positive for troponin. This rate was higher among ICU and deceased patients compared to those in regular wards or who recovered. Al Abbasi et al. in Florida found 27.6% of hospitalized patients had positive troponin and were more likely to die (
17). Similarly, in a study by Garcia de Guadiana-Romualdo et al., more than 12% of patients had positive troponin (
18). The lower troponin threshold in this study may be due to a "borderline" troponin parameter in lab tests. However, troponin positivity in COVID-19 is likely linked to myocardial injury caused by respiratory issues and myocarditis-related hypoxia (
19). In the studied group, only 56.5% had normal ECGs, with sinus tachycardia being the most common at 19%. This increased heart rate may result from physiological responses to infection and fever. Kaliyaperumal et al.’s study of over 300 COVID-19 patients in India found 2.9% had rhythm disorders like atrial fibrillation, and 16.9% showed ST-segment abnormalities. Cardiac rate issues were present in 36.5%, making it the most frequent ECG abnormality in that group (
20). The significant rhythm disorders observed align with Indian research. In this study, sinus tachycardia, bundle branch blocks, atrial fibrillation, and right axis deviation were common during ICU hospitalization.
Echocardiography, performed only in patients with suspected heart failure, showed a 50% prevalence of reduced left ventricular function and 4.2% for right ventricular dysfunction, higher in ICU and deceased patients. Mele et al.’s study of 96 COVID-19 patients found subclinical left ventricular reduction in 90%, highlighting COVID-19’s severe impact on the heart (
21). Pericardial effusion was seen in 6.5% of patients, and pleural effusion in 14.4%, both linked to higher ICU stays and mortality. The effect of pleural effusion was mainly noted with bilateral involvement, indicating more severe illness. Ghantous et al. found pericardial effusion in 14% of COVID-19 patients who all underwent echocardiography, with some showing no symptoms (
22). The higher prevalence of pericardial effusion in Ghantous’ study likely results from all patients, including those without clinical signs, undergoing echocardiography. Vascular complications were also assessed, with cerebral infarction occurring in 2.3% of patients, DVT in 1.4%, and PTE in 14% of patients. Sub-segmental pulmonary embolisms were associated with higher mortality, possibly due to the initial undetected severity. Nannoni et al.’s 2021 meta-analysis estimated ischemic stroke prevalence at around 1.22%, similar to this study, with over 30% of stroke patients dying — much higher than mortality from COVID-19 alone (
23). In this study, the stroke rate among critically ill patients was not significantly elevated, likely due to the inability to transfer some severely ill patients for CT scans. Additionally, Jig Ng’s 2021 meta-analysis reported that approximately 11.1% of COVID-19 patients on prophylactic anticoagulation experienced PTE (
24). This is roughly consistent with the 14% observed in the present study. In our study, all patients received prophylactic anticoagulation since admission.
Demographics, clinical data, and cardiovascular assessments, including ECG and the measurement of relevant biomarkers such as troponin, were included in our study. This study proposes an innovative approach that estimates the risk of ICU admission and death in the short term and provides explanatory explanations to translate key factors such as age, troponin positivity, and ECG changes into understandable and actionable clinical language. This will lead to improved clinical decision-making, optimization of ICU bed allocation in resource-constrained settings, and increased acceptance and trust of the model results by the healthcare team.
5.1. Conclusions
This comprehensive study of 216 COVID-19 patients highlights key cardiovascular complications linked to adverse outcomes, such as ICU admission and mortality. It confirms that advanced age and positive troponin levels are strong predictors of severity and death, aligning with existing research. The study also identified prevalent electrocardiographic abnormalities like sinus tachycardia and rhythm disturbances, along with significant reductions in ventricular function, especially in severe cases. Fluid buildup, such as pericardial and bilateral pleural effusions, was associated with a worse prognosis, while vascular issues like PTE, particularly sub-segmental types, significantly increased mortality risks. Overall, these findings emphasize the importance of personalized cardiovascular monitoring in COVID-19 management to improve risk assessment and clinical outcomes.
5.2. Limitations
This study provides valuable insights into COVID-19's cardiovascular impacts but has several limitations. Its retrospective, single-center design restricts causal inferences and may involve incomplete data, especially for subclinical conditions. The findings may not be generalizable due to selection bias, as only hospitalized patients were included, excluding milder cases, and recent data sharing restrictions limit transparency. Unmeasured confounders, like socioeconomic factors and treatment variations, could influence results. Diagnostic tools used may have varying accuracy, and the study's design prevents establishing a direct temporal link between COVID-19 and cardiovascular outcomes. Additionally, evolving clinical practices mean the findings may not reflect current care standards, highlighting the need for prospective, multicenter studies with broader data collection to validate and expand these observations.